172 related articles for article (PubMed ID: 37589218)
21. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
22. Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
Steenbruggen TG; Bouwer NI; Smorenburg CH; Rier HN; Jager A; Beelen K; Ten Tije AJ; de Jong PC; Drooger JC; Holterhues C; Kitzen JJEM; Levin M-; Sonke GS
Breast Cancer Res Treat; 2019 Dec; 178(3):597-605. PubMed ID: 31493033
[TBL] [Abstract][Full Text] [Related]
23. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
Krasniqi E; Pizzuti L; Barchiesi G; Sergi D; Carpano S; Botti C; Kayal R; Sanguineti G; Marchetti P; Botticelli A; Marinelli D; Gamucci T; Natoli C; Grassadonia A; Tinari N; Tomao S; Tonini G; Santini D; Michelotti A; Mentuccia L; Vaccaro A; Magnolfi E; Gelibter A; Magri V; Cortesi E; D'Onofrio L; Cassano A; Cazzaniga M; Moscetti L; Fabbri A; Scinto AF; Corsi D; Carbognin L; Bria E; La Verde N; Garufi C; Di Stefano P; Mirabelli R; Veltri E; Paris I; Giotta F; Lorusso V; Landucci E; Ficorella C; Roselli M; Adamo V; Ricciardi G; Russo A; Valerio MR; Berardi R; Pistelli M; Cannita K; Zamagni C; Garrone O; Baldini E; Livi L; Meattini I; Del Medico P; Generali D; De Maria R; Risi E; Ciliberto G; Villa A; Sperduti I; Mazzotta M; Barba M; Giordano A; Vici P
J Cell Physiol; 2020 Nov; 235(11):7900-7910. PubMed ID: 31943171
[TBL] [Abstract][Full Text] [Related]
24. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
25. Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
Lambertini M; Agbor-Tarh D; Metzger-Filho O; Ponde NF; Poggio F; Hilbers FS; Korde LA; Chumsri S; Werner O; Del Mastro L; Caparica R; Moebus V; Moreno-Aspitia A; Piccart MJ; de Azambuja E
ESMO Open; 2020 Nov; 5(6):e000979. PubMed ID: 33154022
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
Moinard-Butot F; Saint-Martin C; Pflumio C; Carton M; Jacot W; Cottu PH; Diéras V; Dalenc F; Goncalves A; Debled M; Patsouris A; Mouret-Reynier MA; Vanlemmens L; Leheurteur M; Emile G; Ferrero JM; Desmoulins I; Uwer L; Eymard JC; Cheaib B; Courtinard C; Bachelot T; Chevrot M; Petit T
Breast; 2022 Jun; 63():54-60. PubMed ID: 35299035
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.
Ali S; Hendry J; Le D; Mondal PK; Sami A; Chalchal H; Haider K; Ahmed O; El-Gayed A; Wright P; Pauls M; Johnson K; Ahmed S
Sci Rep; 2022 Jan; 12(1):1068. PubMed ID: 35058536
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
Kaczmarek E; Saint-Martin C; Pierga JY; Brain E; Rouzier R; Savignoni A; Mouret-Fourme E; Dieras V; Piot I; Dubot C; Carton M; Lerebours F
Breast Cancer Res Treat; 2019 Dec; 178(3):505-512. PubMed ID: 31486993
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab and survival of patients with metastatic breast cancer.
Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
[TBL] [Abstract][Full Text] [Related]
30. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
31. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
Blackwell K; Gligorov J; Jacobs I; Twelves C
Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
[TBL] [Abstract][Full Text] [Related]
32. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
34. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.
Kaufman PA; Brufsky AM; Mayer M; Rugo HS; Tripathy D; Yood MU; Feng S; Wang LI; Quah CS; Yardley DA
Breast Cancer Res Treat; 2012 Oct; 135(3):875-83. PubMed ID: 22923238
[TBL] [Abstract][Full Text] [Related]
35. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S
Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
[TBL] [Abstract][Full Text] [Related]
38. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
Trials; 2020 May; 21(1):391. PubMed ID: 32381018
[TBL] [Abstract][Full Text] [Related]
39. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.
Murthy RK; Varma A; Mishra P; Hess KR; Young E; Murray JL; Koenig KH; Moulder SL; Melhem-Bertrandt A; Giordano SH; Booser D; Valero V; Hortobagyi GN; Esteva FJ
Cancer; 2014 Jul; 120(13):1932-8. PubMed ID: 24677057
[TBL] [Abstract][Full Text] [Related]
40. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
